DCF — ROSWELL PARK CANCER INSTITUTE
Enterprise Value: $-683.1M
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$-683.1M
Enterprise Value
$-228.5M
PV of Cash Flows
$-454.6M
PV of Terminal Value
$-732.1M
Terminal Value
10.0%
WACC
2.5%
Terminal Growth
Cash Flow Projections
PROJ| Year | Revenue | EBITDA | Margin | FCF | PV(FCF) |
|---|---|---|---|---|---|
| Year 1 | $795.5M | $-35.8M | -5.0% | $-69.5M | $-63.2M |
| Year 2 | $819.4M | $-28.7M | -4.0% | $-63.4M | $-52.4M |
| Year 3 | $844.0M | $-21.1M | -3.0% | $-56.8M | $-42.7M |
| Year 4 | $869.3M | $-17.4M | -2.0% | $-54.2M | $-37.0M |
| Year 5 | $895.4M | $-15.7M | -2.0% | $-53.6M | $-33.3M |
Interpretation
INTAt a WACC of 10.0% and terminal growth of 2.5%, enterprise value is $-683.1M. Terminal value accounts for 0% of total EV — consider sensitivity to terminal assumptions.
Next steps: Check the LBO model to see equity returns at this entry price, or the EBITDA bridge to model value creation levers.
Assumptions
ASSMrevenue base$772.3M
revenue growth rates[0.03, 0.03, 0.03, 0.03, 0.03]
ebitda margin base-0.05
ebitda margin improvement bps[50, 100, 100, 50, 25]
capex pct revenue0.04
nwc pct revenue0.08
tax rate0.25
projection years5